1-Tert-butyl-2,4,5-trimethylpiperazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-Tert-butyl-2,4,5-trimethylpiperazine
• 英文别名: 1-tert-butyl-2,4,5-trimethylpiperazine
• 化学式: C₁₁H₂₄N₂
• 分子量: 184.32
• InChiKey: LRDMGKMRXZSECC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Resorcinol derivatives
  申请人：Sutter West Bay Hospitals

  公开号：US10202322B2

  公开（公告）日：2019-02-12

  The disclosure relates to cannabinoid derivative compounds, pharmaceutical compositions made thereof, and methods for treating various diseases and disorders including cancer.

  本公开涉及大麻素衍生物化合物、由其制成的药物组合物以及治疗包括癌症在内的各种疾病和失调的方法。
• Indole derivatives as estrogen receptor degraders
  申请人：Arvinas Operations, Inc.

  公开号：US10865202B2

  公开（公告）日：2020-12-15

  The present disclosure relates to compounds and a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing the compounds, and processes for their preparation. The disclosure also relates to the use of the compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of the estrogen receptor, including degrading the estrogen receptor, the treatment of diseases and conditions mediated by the estrogen receptor.

  本公开涉及化合物及其药学上可接受的盐、含有这些化合物的组合物、组合剂和药物，以及它们的制备工艺。本公开还涉及这些化合物、组合物、组合物和药物的用途，例如作为雌激素受体活性的抑制剂，包括降解雌激素受体，治疗由雌激素受体介导的疾病和病症。
• RESORCINOL DERIVATIVES
  申请人：Sutter West Bay Hospitals

  公开号：US20180170846A1

  公开（公告）日：2018-06-21

  The disclosure relates to cannabinoid derivative compounds, pharmaceutical compositions made thereof, and methods for treating various diseases and disorders including cancer.
• INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS
  申请人：Arvinas Operations, Inc.

  公开号：US20190233408A1

  公开（公告）日：2019-08-01

  The present disclosure relates to compounds and a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing the compounds, and processes for their preparation. The disclosure also relates to the use of the compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of the estrogen receptor, including degrading the estrogen receptor, the treatment of diseases and conditions mediated by the estrogen receptor.
• BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas Operations, Inc.

  公开号：US20200038378A1

  公开（公告）日：2020-02-06

  The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.